Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple MyelomaChristina M. Annunziata, Louis M. Staudt, Sandeep S. Davé et al.|Cancer Cell|2007Cited by 949
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Shinsan M. Su, Jeremy Travins et al.|Cancer Discovery|2017Cited by 457
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphomaMichael A. Milhollen, Peter G. Smith, Tary Traore et al.|Blood|2010Cited by 323
A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell diseaseJulia Xu, Swee Lay Thein, Anna Conrey et al.|Blood|2022Cited by 72
Mitapivat (AG-348) Demonstrates Safety, Tolerability, and Improvements in Anemia, Hemolysis, Oxygen Affinity, and Hemoglobin S Polymerization Kinetics in Adults with Sickle Cell Disease: A Phase 1 Dose Escalation StudyJulia Xu, Swee Lay Thein, Anna Conrey et al.|Blood|2021Cited by 9